Traws Pharma Net Income
| TRAW Stock | 1.60 0.37 18.78% |
As of the 19th of February, Traws Pharma has the Risk Adjusted Performance of 0.0395, coefficient of variation of 2613.5, and Semi Deviation of 9.16. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Traws Pharma, as well as the relationship between them. Please validate Traws Pharma mean deviation, information ratio, as well as the relationship between the Information Ratio and downside variance to decide if Traws Pharma is priced more or less accurately, providing market reflects its prevalent price of 1.6 per share. Please also confirm Traws Pharma total risk alpha, which is currently at (0.09) to double-check the company can sustain itself at a future point.
Traws Pharma Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 3.0789 | Revenue | Earnings Share (1.82) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -62.9 M | -66 M | |
| Net Loss | -149.9 M | -142.4 M | |
| Net Loss | (31.69) | (33.28) | |
| Net Income Per E B T | 0.38 | 0.36 |
Traws | Net Income | Build AI portfolio with Traws Stock |
The evolution of Net Income for Traws Pharma provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Traws Pharma compares to historical norms and industry peers.
Latest Traws Pharma's Net Income Growth Pattern
Below is the plot of the Net Income of Traws Pharma over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Traws Pharma financial statement analysis. It represents the amount of money remaining after all of Traws Pharma operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Traws Pharma's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Traws Pharma's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (54.67 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Traws Net Income Regression Statistics
| Arithmetic Mean | (35,038,350) | |
| Coefficient Of Variation | (53.95) | |
| Mean Deviation | 16,108,377 | |
| Median | (25,157,000) | |
| Standard Deviation | 18,904,837 | |
| Sample Variance | 357.4T | |
| Range | 49.9M | |
| R-Value | (0.14) | |
| Mean Square Error | 373.7T | |
| R-Squared | 0.02 | |
| Significance | 0.59 | |
| Slope | (526,756) | |
| Total Sum of Squares | 5718.3T |
Traws Net Income History
Other Fundumenentals of Traws Pharma
Traws Pharma Net Income component correlations
Traws Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Traws Pharma is extremely important. It helps to project a fair market value of Traws Stock properly, considering its historical fundamentals such as Net Income. Since Traws Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Traws Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Traws Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
What growth prospects exist in Pharmaceuticals sector? Can Traws capture new markets? Factors like these will boost the valuation of Traws Pharma. If investors know Traws will grow in the future, the company's valuation will be higher. Valuation analysis balances hard financial data with qualitative growth assessments. While each Traws Pharma valuation metric matters, prioritizing which indicators carry greater predictive weight remains essential.
Earnings Share (1.82) | Revenue Per Share | Quarterly Revenue Growth 46.947 | Return On Assets | Return On Equity |
The market value of Traws Pharma is measured differently than its book value, which is the value of Traws that is recorded on the company's balance sheet. Investors also form their own opinion of Traws Pharma's value that differs from its market value or its book value, called intrinsic value, which is Traws Pharma's true underlying value. Investment professionals apply varied valuation frameworks to compute inherent worth and acquire positions when market prices trade at discounts to calculated value. Because Traws Pharma's market value can be influenced by many factors that don't directly affect Traws Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Traws Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Traws Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Traws Pharma's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Traws Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Traws Pharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Traws Pharma.
| 11/21/2025 |
| 02/19/2026 |
If you would invest 0.00 in Traws Pharma on November 21, 2025 and sell it all today you would earn a total of 0.00 from holding Traws Pharma or generate 0.0% return on investment in Traws Pharma over 90 days. Traws Pharma is related to or competes with Cingulate, Dogwood Therapeutics, Imunon, Cocrystal Pharma, Sensei Biotherapeutics, Bolt Biotherapeutics, and Mustang Bio. Traws Pharma is entity of United States. It is traded as Stock on NASDAQ exchange. More
Traws Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Traws Pharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Traws Pharma upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 9.78 | |||
| Information Ratio | 0.0336 | |||
| Maximum Drawdown | 58.96 | |||
| Value At Risk | (12.90) | |||
| Potential Upside | 17.7 |
Traws Pharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Traws Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Traws Pharma's standard deviation. In reality, there are many statistical measures that can use Traws Pharma historical prices to predict the future Traws Pharma's volatility.| Risk Adjusted Performance | 0.0395 | |||
| Jensen Alpha | 0.3534 | |||
| Total Risk Alpha | (0.09) | |||
| Sortino Ratio | 0.0346 | |||
| Treynor Ratio | 0.6323 |
Traws Pharma February 19, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0395 | |||
| Market Risk Adjusted Performance | 0.6423 | |||
| Mean Deviation | 6.84 | |||
| Semi Deviation | 9.16 | |||
| Downside Deviation | 9.78 | |||
| Coefficient Of Variation | 2613.5 | |||
| Standard Deviation | 10.07 | |||
| Variance | 101.31 | |||
| Information Ratio | 0.0336 | |||
| Jensen Alpha | 0.3534 | |||
| Total Risk Alpha | (0.09) | |||
| Sortino Ratio | 0.0346 | |||
| Treynor Ratio | 0.6323 | |||
| Maximum Drawdown | 58.96 | |||
| Value At Risk | (12.90) | |||
| Potential Upside | 17.7 | |||
| Downside Variance | 95.56 | |||
| Semi Variance | 83.92 | |||
| Expected Short fall | (7.66) | |||
| Skewness | 0.033 | |||
| Kurtosis | 2.92 |
Traws Pharma Backtested Returns
Traws Pharma appears to be dangerous, given 3 months investment horizon. Traws Pharma owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.023, which indicates the firm had a 0.023 % return per unit of risk over the last 3 months. We have found twenty-seven technical indicators for Traws Pharma, which you can use to evaluate the volatility of the company. Please review Traws Pharma's Risk Adjusted Performance of 0.0395, semi deviation of 9.16, and Coefficient Of Variation of 2613.5 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Traws Pharma holds a performance score of 1. The entity has a beta of 0.59, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Traws Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Traws Pharma is expected to be smaller as well. Please check Traws Pharma's total risk alpha, as well as the relationship between the downside variance and day median price , to make a quick decision on whether Traws Pharma's existing price patterns will revert.
Auto-correlation | -0.11 |
Insignificant reverse predictability
Traws Pharma has insignificant reverse predictability. Overlapping area represents the amount of predictability between Traws Pharma time series from 21st of November 2025 to 5th of January 2026 and 5th of January 2026 to 19th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Traws Pharma price movement. The serial correlation of -0.11 indicates that less than 11.0% of current Traws Pharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.11 | |
| Spearman Rank Test | -0.33 | |
| Residual Average | 0.0 | |
| Price Variance | 0.19 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Traws Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Traws Pharma reported net income of (54.67 Million). This is 116.02% lower than that of the Pharmaceuticals sector and 178.05% lower than that of the Health Care industry. The net income for all United States stocks is 109.58% higher than that of the company.
Traws Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Traws Pharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Traws Pharma could also be used in its relative valuation, which is a method of valuing Traws Pharma by comparing valuation metrics of similar companies.Traws Pharma is currently under evaluation in net income category among its peers.
Traws Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Traws Pharma from analyzing Traws Pharma's financial statements. These drivers represent accounts that assess Traws Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Traws Pharma's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 42.9M | 13.6M | 15.7M | 13.8M | 15.9M | 15.1M | |
| Enterprise Value | (12.1M) | (25.2M) | (5.1M) | (7.6M) | (8.7M) | (8.2M) |
Traws Fundamentals
| Return On Equity | -10.6 | ||||
| Return On Asset | -0.92 | ||||
| Operating Margin | (5.55) % | ||||
| Current Valuation | 8.92 M | ||||
| Shares Outstanding | 7.99 M | ||||
| Shares Owned By Insiders | 13.13 % | ||||
| Shares Owned By Institutions | 23.72 % | ||||
| Number Of Shares Shorted | 505.71 K | ||||
| Price To Book | 3.34 X | ||||
| Price To Sales | 5.50 X | ||||
| Revenue | 226 K | ||||
| Gross Profit | 2.85 M | ||||
| EBITDA | (166.51 M) | ||||
| Net Income | (54.67 M) | ||||
| Total Debt | 56.59 M | ||||
| Book Value Per Share | 0.64 X | ||||
| Cash Flow From Operations | (29.79 M) | ||||
| Short Ratio | 0.15 X | ||||
| Earnings Per Share | (1.82) X | ||||
| Target Price | 8.0 | ||||
| Beta | 1.75 | ||||
| Market Capitalization | 19.42 M | ||||
| Total Asset | 24.96 M | ||||
| Retained Earnings | (649.15 M) | ||||
| Working Capital | 13.42 M | ||||
| Net Asset | 24.96 M |
About Traws Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Traws Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Traws Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Traws Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Traws Stock Analysis
When running Traws Pharma's price analysis, check to measure Traws Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Traws Pharma is operating at the current time. Most of Traws Pharma's value examination focuses on studying past and present price action to predict the probability of Traws Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Traws Pharma's price. Additionally, you may evaluate how the addition of Traws Pharma to your portfolios can decrease your overall portfolio volatility.